• Yes, there was more good news today aside from Human Genome Sciences (HGSI). Orexigen (OREX) also announced positive data from its Contrave obesity trial. [Reuters]

• Selling Bextra off-label? Pfizer (PFE) rep gets cush’ home confinement. [BNET Pharma]

• 300 new jobs in Atlanta? Maybe, says Dendreon (DNDN). [Xconomy]

• Rejected: Labopharm (DDSS) gets complete response from FDA for once daily Trazodone to treat depression – no new studies needed. [TransWorldNews]

• It might cost the taxpayers a hefty penny to pay for these swine flu vaccines, but big pharma is getting the last laugh. [Financial Times]

• Nycomed files Daxas NDA, has “potential partners” lined up — uh, yeah. [PharmaTimes]

• VC’s like biotech again. [FierceBiotech]

• Finally, the FDA has accepted Spectrum Pharmaceuticals’ (SPPI) response for Zevalin. New PDUFA date on September 7, 2009. [EarthTimes]

Anonymous Tip? Comments? Contact us: hr AT iguanabio DOT com

Related Posts